Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: Curbstone who wrote (288)	12/11/1998 12:54:00 PM
From: Bear Down	Read Replies (2) \| Respond to of 1084

I think there is still a good 25% downside left. And as far as never telling about getting stung, ENVY stung me BAD. does that make you feel better!!!!! It is amazing how you select and choose who you wish to have pain inflicted on. I never wish anything bad on any long. Just because I short your overhyped garbage does not mean i want you to lose money. I hope you are smart enough to sell with me, save your money, drive down the price, and let me profit. just seems like good business sense to me. I hope this procedure says a million lives as well. I just hope the stock stays in the shitter long enough for me to make a killing!!!!!

To: Curbstone who wrote (288)	12/11/1998 2:03:00 PM
From: John Miz	Read Replies (1) \| Respond to of 1084

Back when Cowen initiated coverage of this stock, (in March of 1997) their initial price target was 15 dollars per share. In his report, the analyst called for an EPS breakout to $1.00 F2000, and $2.85 in F2001. The Aastrom system was described as being "a razor and blade" business model with compelling revenue and EPS potential. They called the technology commercially practical and easy to use. I think the European launch of this product, coming shortly, should help out the price of ASTM. (500MM+ market) Don't know if Cowen is currently following ASTM. John